



Your pharmacy's guide to **SAVINGS AND SUPPORT FOR QULIPTA® PATIENTS**

HOW TO PROCESS THE QULIPTA® COMPLETE SAVINGS CARD

> **Submit the claim to the primary Third-Party Payer first**, then submit the balance due to IQVIA using BIN #601341 as a Secondary Payer COB with patient responsibility amount and a valid **Other Coverage Code 08**.



Not actual card.

> **If you receive a rejection due to PA, NDC Block, or Product Not Covered, submit Other Coverage Code 03 (secondary claim). Eligible commercially insured patients may pay as little as \$0. Reimbursement will be received from IQVIA.** For any questions, call IQVIA at **1-800-364-4767**. Help is available to navigate the QULIPTA Complete Savings Card redemption process, including processing in case of PA, NDC Block, Product Not Covered, and pharmacy-specific coupon processing questions.

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS

Dose modifications are recommended when using the following:

- Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
- Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information or visit rxabbvie.com/pdf/QULIPTA_pi.pdf.

HELP PATIENTS SAVE ON QULIPTA[®]

Eligible commercially insured patients may pay as little as \$0* for QULIPTA—3 ways to enroll:



Text ENROLL to 785478[†]



Scan here for savings and support information



Visit QULIPTA.com/savings

*Eligibility: Available to patients with commercial insurance coverage for QULIPTA[®] (atogepant) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com. For additional information, call 1-855-QULIPTA (1-855-785-4782). To learn about AbbVie's privacy practices and your privacy choices, visit <https://privacy.abbvie>.

[†]Msg and data rates apply. Msg frequency depends on user. Reply HELP for help; reply STOP to cancel. Consent to texts not required to sign up for offer. To learn about AbbVie's privacy practices and your privacy choices, visit <https://privacy.abbvie>.

QULIPTA DOSING

RECOMMENDED DOSES

EPISODIC MIGRAINE

10 mg, 30 mg, or 60 mg taken once daily.

CHRONIC MIGRAINE

60 mg taken once daily.



IMPORTANT SAFETY INFORMATION (cont'd)

USE IN SPECIFIC POPULATIONS

Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information or visit rxabbvie.com/pdf/QULIPTA_pi.pdf.

Reference: 1. QULIPTA (atogepant). Package insert. AbbVie Inc; 2023.

© 2023 AbbVie. All rights reserved.

QULIPTA[®] and its design are registered trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.

US-QLP-230443 08/23

**QULIPTA[®]**
(atogepant) tablets